Pharmaceuticals Kenya

Kenya Gene Therapy for Hemophilia Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Kenya Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Kenya · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $0.3 Mn Placeholder estimate
Estimate 2025 $0.3 Mn 0.1% of the global market
Projected 2034 $4.0 Mn 1,051.9% Adds $3.6 Mn over 9 forecast years
CAGR 2025–2034 31.2% Faster than 97% of 183 Pharmaceuticals markets here
Key players 5
  • Kenya is 0.07% of the global market.
  • In Africa, the largest is South Africa at $3.8 Mn.
  • Fastest growing: Egypt at 31.4% a year.
  • Kenya ranks 3rd of 3 by size in Africa.

Market size projection

Kenya

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Gene Therapy for Hemophilia Market market size by year, Kenya
YearMarket sizeChange that yearSince 2025
2024 (estimate) $0.3 Mn — —
2025 (base) $0.3 Mn +$0.1 Mn —
2026 (forecast) $0.5 Mn +$0.1 Mn +31.2%
2027 (forecast) $0.6 Mn +$0.1 Mn +72.1%
2028 (forecast) $0.8 Mn +$0.2 Mn +125.8%
2029 (forecast) $1.0 Mn +$0.2 Mn +196.3%
2030 (forecast) $1.3 Mn +$0.3 Mn +288.7%
2031 (forecast) $1.8 Mn +$0.4 Mn +410%
2032 (forecast) $2.3 Mn +$0.5 Mn +569.2%
2033 (forecast) $3.0 Mn +$0.7 Mn +778%
2034 (forecast) $4.0 Mn +$0.9 Mn +1,051.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Kenya Gene Therapy for Hemophilia Market Analysis at a glance
Market size, 2025$0.3 Mn placeholder estimate
Forecast, 2034$4.0 Mn placeholder estimate
Growth (CAGR), 2025–203431.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, vector and end user (see all)
Key playersBioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all)
Regulator in KenyaPPBSource: Pharmacy and Poisons Board. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Kenya Gene Therapy for Hemophilia Market Analysis Executive Summary

Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.

Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).

Bar chart: Kenya Gene Therapy for Hemophilia market size, 2024–2034, placeholder estimates. $0.3 Mn in 2024, $0.3 Mn in 2025 and $4.0 Mn in 2034, 31.2% CAGR.
Kenya Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Kenya Gene Therapy for Hemophilia Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Gene Therapy for Hemophilia Market in Kenya

The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in Kenya

Gene Therapy for Hemophilia in Kenya: rules and payment

The Pharmacy and Poisons Board (PPB) registers medicines before sale.⁠[1] The Social Health Authority (SHA) replaced the National Health Insurance Fund (NHIF) in October 2024.⁠[2]

[1] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[2] Social Health Authority. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Kenya.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gene Therapy for Hemophilia in context

Kenya compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.29 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 3.0% of people (2025). World: 10.4% of people (2025). 10th highest of the 17 countries we cover in Africa.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Gene Therapy for Hemophilia market in Kenya?
Placeholder estimate: about $0.3 Mn in 2025, rising to about $4.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in Kenya growing?
Placeholder estimate: about 31.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Who regulates Gene Therapy for Hemophilia in Kenya?
The Pharmacy and Poisons Board (PPB) registers medicines before sale. Source: Pharmacy and Poisons Board. Checked 14 Nov 2026.
How is healthcare paid for in Kenya?
The Social Health Authority (SHA) replaced the National Health Insurance Fund (NHIF) in October 2024. Source: Social Health Authority. Checked 14 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Kenya

See all

Related on cell and gene therapy and rare diseases

See the topic